Fox Run Management, L.L.C. I Teos Therapeutics, Inc. Transaction History
Fox Run Management, L.L.C.
- $526 Million
- Q4 2024
A detailed history of Fox Run Management, L.L.C. transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 37,838 shares of ITOS stock, worth $280,379. This represents 0.06% of its overall portfolio holdings.
Number of Shares
37,838
Previous 19,263
96.43%
Holding current value
$280,379
Previous $196,000
47.96%
% of portfolio
0.06%
Previous 0.05%
Shares
5 transactions
Others Institutions Holding ITOS
# of Institutions
150Shares Held
33.4MCall Options Held
454KPut Options Held
2.45M-
Black Rock Inc. New York, NY3.73MShares$27.6 Million0.0% of portfolio
-
Mpm Asset Management LLC Cambridge, MA2.74MShares$20.3 Million16.91% of portfolio
-
Bvf Inc San Francisco, CA2.33MShares$17.2 Million0.67% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.09MShares$15.5 Million0.26% of portfolio
-
Jpmorgan Chase & CO New York, NY2.07MShares$15.3 Million0.0% of portfolio
About iTeos Therapeutics, Inc.
- Ticker ITOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,575,300
- Market Cap $264M
- Description
- Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...